市場調查報告書

分子診斷的全球市場 - 分析、預測 (2018-2028年):感染疾病,遺傳基因檢驗,血液捐贈者篩檢,癌症,人類白血球型抗原 (HLA) 檢驗,NIPT (非侵入性產前檢查) 、搭配診斷,液態切片

Global Molecular Diagnostics Market: Focus on Product Type (Kits and Consumables, Systems, Software & Others), Applications, Technologies, End-User, Country Data (15 Countries) and Competitive Landscape, Analysis and Forecast 2018-2028

出版商 BIS Research Inc. 商品編碼 778296
出版日期 內容資訊 英文 358 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
分子診斷的全球市場 - 分析、預測 (2018-2028年):感染疾病,遺傳基因檢驗,血液捐贈者篩檢,癌症,人類白血球型抗原 (HLA) 檢驗,NIPT (非侵入性產前檢查) 、搭配診斷,液態切片 Global Molecular Diagnostics Market: Focus on Product Type (Kits and Consumables, Systems, Software & Others), Applications, Technologies, End-User, Country Data (15 Countries) and Competitive Landscape, Analysis and Forecast 2018-2028
出版日期: 2019年01月23日內容資訊: 英文 358 Pages
簡介

全球分子診斷市場預計至2028年將成長至296億8,000萬美元的規模。

本報告提供全球分子診斷市場調查,市場概要,市場成長的各種影響因素及市場機會分析,競爭分析與市場佔有率,法規環境,各市場區隔、各地區的趨勢與市場規模的變化與預測,主要企業簡介等資訊彙整。

第1章 市場概要

第2章 市場動態

  • 概要
  • 冰山分析
  • 影響分析
  • 市場成長的促進因素
  • 市場成長的阻礙因素
  • 市場機會

第3章 競爭環境

  • 主要策略、發展
  • 市場佔有率分析
  • 成長佔有率分析 (機會製圖)
  • 產業的魅力

第4章 法律規範

  • 美國
  • 歐洲
  • 亞太地區
    • 中國
    • 日本

第5章 全球分子診斷市場:各產品

  • 概要
  • 套件、消耗品
  • 系統
  • 軟體、其他產品

第6章 全球分子診斷市場:各用途

  • 概要
  • 主要的分子診斷
    • 感染疾病
    • 遺傳基因檢驗
    • 血液捐贈者篩檢
    • 癌症 (搭配診斷、液態切片除外)
    • 人白血球型抗原 (HLA) 檢驗
    • 其他用途
  • NIPT (非侵入性產前檢查)
  • 搭配診斷
  • 液態切片

第7章 全球分子診斷市場:各技術

  • 概要
  • 聚合酵素鏈鎖反應 (PCR)
  • 定序
  • 微陣列
  • In-situ 雜合反應
  • 免疫組織化學
  • 核酸增幅檢查
  • 等溫放大
  • 其他

第8章 全球分子診斷市場:各終端用戶

  • 概要
  • 醫院
  • 診斷中心
  • 門診病人診療所/綜合診療醫生
  • 研究實驗室

第9章 全球分子診斷市場:各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他 (ROW)

第10章 企業簡介

  • 概要
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • bioMerieux S.A.
  • Bio-Rad Laboratories, Inc.
  • Cynvenio Biosystems, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • GUARDANT HEALTH, INC
  • Illumina, Inc.
  • Invivoscribe Technologies, Inc.
  • MolecularMD Corporation
  • QIAGEN N.V.
  • Siemens Healthineers, Inc.
  • Thermo Fisher Scientific Inc.
  • QuantuMDx Group Ltd.
  • HTG Molecular Diagnostics, Inc.

第11章 調查範圍、調查手法

目錄
Product Code: BH089A

Global Molecular Diagnostics Market to Reach $29.68 Billion by 2028

Since the dawn of the precision medicine era, the entire gamut of the healthcare industry has witnessed a paradigm change toward more precise diagnostics. The increasing prevalence of chronic disorders and an overall increased demand for preventive medication with minimal/no side-effect are promoting the growth of the global molecular diagnostics market, providing platform for the designing and development of highly enhanced and optimum products that would direct patients to their appropriate treatment modules. These individualized care regimes are improving the quality of life of the patients and reducing economic, societal, and clinical burden, projecting a future of prosperity.

Presently, product categories within the molecular diagnostics market include kits and consumables, systems, and software and others. Till date, the healthcare industry has witnessed a number of successful products that have contributed significantly in enhancing the technological advancements in making molecular diagnostics more precise. However, the consistent evolution of the market has further necessitated the insurgence of more advanced research initiatives that look to devise the optimum assay with the confluence of multiplexing and low cost. Additionally, with systems being developed at the interface of different technologies, precision diagnostics is soon to become a widespread reality.

The purpose of the study is to gain a holistic view of the global molecular diagnostics market in terms of various factors, including regulatory reforms and technological advancements, which are influencing the market. The market has been segmented into 'products', 'applications', 'technologies', 'end-users', and 'regions'. The scope of this report is centered upon conducting a detailed study of the products allied with the molecular diagnostics market. In addition, the study also includes the exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each product, application, technology, end-user, region, and companies, as well as other vital information with respect to molecular diagnostics market. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global molecular diagnostics market with the help of the key factors driving the market, the restraints, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

The research study highlights the factors governing the industry attractiveness with Porter's Five Forces for a comprehensive understanding of the global molecular diagnostics market. Moreover, the study includes detailed product mapping, market estimation, and analysis of key trends in multiple geographical regions, growth of molecular diagnostics market in each region for different applications, and the key strategies and developments by the prominent molecular diagnostics manufacturers.

The answers to the following key questions can be derived from this report:

  • What are the major market drivers, challenges, and opportunities in the global molecular diagnostics market?
  • What are the underlying structures resulting in the emerging trends within the global molecular diagnostics market?
  • How will each segment of the global molecular diagnostics market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2028?
  • What are the key developmental strategies which are implemented by the major players in order to sustain in the competitive market? What are the key regulatory implications in developed and developing regions for molecular diagnostics?
  • Who are the leading players with significant offerings to the global molecular diagnostics market? What is the current market dominance for each of these leading players?
  • What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2018-2028? Which molecular diagnostic product type is having the most promising growth?
  • What are the key applications in global molecular diagnostics market? What are the major segments of these applications? What technologies are dominating these application segments?
  • What are the major technologies that are employed in the global molecular diagnostics market? Which is the dominating technology?
  • Who are the primary end-users of the global molecular diagnostics market? Which is the fastest growing end-use segment in the global molecular diagnostics market?
  • Who are the key manufacturers in the global molecular diagnostics market, and what are their contributions? Also, what is the growth potential of each major molecular diagnostics manufacturer?
  • What is the scope of the global molecular diagnostics market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which molecular diagnostics application dominates these regions?

Key trends targeted in the report:

  • What are the emerging trends in the global molecular diagnostics market? How are these trends revolutionizing the diagnostic procedure?
  • Which technologies are anticipated to break-through the current molecular diagnostic regime?
  • Which companies are anticipated to be highly disruptive in the future and why?
  • What are the regulatory procedures that are required to unify the approval process for emerging molecular diagnostics? How will they enhance the reimbursement scenario?
  • What are the gaps in regularizing optimum molecular diagnostic adoption in regular healthcare routines? How are these gaps being tackled?

The key manufacturers who have been contributing significantly to the global molecular diagnostics market include Abbott Laboratories, Agilent Technologies, Inc., Becton, Dickinson and Company, bioMerieux S.A., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Illumina, Inc., QIAGEN N.V., Siemens Healthineers, Inc., and Thermo Fisher Scientific Inc., among others.

Executive Summary

As the World Health Organization states, the global healthcare expenditure is on course to be an exorbitant $8.5 trillion in 2020, owing to an increasing economic burden of chronic diseases, which are estimated to constitute almost 43% of the global economic burden. Thus, the soaring demand for better treatment outcome is leading to an ascending need for preventive, precise healthcare, and tailored medication. The growth of the precision medicine market over the last few years (2010-2017) has been colossal and has significantly contributed to giving rise to a number of parallel fields of study and possible healthcare implementations. Molecular diagnostics have revolutionized the overall precision medicine industry by adopting highly advancing technologies, further giving rise to several inclusive applications including core molecular diagnostics, companion diagnostics, liquid biopsy, and non-invasive prenatal testing.

As one of the most transformative, and dynamic areas of diagnostics, molecular diagnostics have made significant strides in research and treatment dissemination that have been continuously revolutionizing healthcare across a broad continuum of diseases and health conditions. The evolution of molecular diagnostics into a more integrative aspect of healthcare routines has been widely established by significant laboratory tests in infectious disease and genetic screening, and a continuously increasing number in oncology. The insurgence of massively parallel methods is increasingly allowing the sequencing of entire genomes at very low costs. Further, owing to the rapid advancements being undertaken in the industry and being led by revolutionary initiatives of developing mobile point-of-care systems and optimizing assays with the confluence of multiplexing at low costs, the global molecular diagnostics industry is set to witness significant evolution into more precise and accurate diagnostics. With a critical role in the global precision medicine phenomenon, molecular diagnostics are responsible for ensuring safe and effective application of targeted therapeutics, thus enabling better care with the ultimate aim of lowering the economic burden of diseases on populations.

The increasing prevalence of chronic disorders and an overall increased demand for preventive medication with minimal/no side-effect are promoting the growth of the global molecular diagnostics market, providing platform for the designing and development of highly enhanced and optimum products that would direct patients to their appropriate treatment modules. These individualized care regimes are improving quality of life of the patients and reducing economic, societal, and clinical burden, projecting a future of prosperity.

Presently, product categories within the molecular diagnostics market include kits and consumables, systems, and software and others. Till date, the healthcare industry has witnessed a number of successful products that have contributed significantly to the enhancement of technological advancements in making molecular diagnostics more precise. However, the consistent evolution of the market has further necessitated the insurgence of more advanced research initiatives that look to devise the optimum assay with the confluence of multiplexing and low cost. Additionally, with systems being developed at the interface of different technologies, precision diagnostics is soon to become a widespread reality.

As of 2018, the molecular diagnostics can be seen to have exposure in almost all the developed countries. However, with the rapid advancements taking place and an exponential progression in the number of companies entering the space, access to consumers is bound to become easier, thus significantly increasing the exposure in less-developed countries. The global molecular diagnostics market has been witnessing a steady growth since the end of the Human Genome Project in 2003. The market is expected to continue to grow with a double digit CAGR of 10.89% during the forecast period, 2018-2028. Growing at a CAGR of 11.08% during the forecast period of 2018-2028, the kits and consumables product segment is anticipated to generate a value of $20.33 billion in 2028. However, the global market for software and other products is anticipated to grow at the fastest CAGR of 11.74% during the forecast period 2018-2028.

The purpose of the study is to gain a holistic view of the global molecular diagnostics market in terms of various factors, such as recent trends and product advancements, influencing the market. The scope of this report is centered upon conducting a detailed study of the products allied with the molecular diagnostics market, which includes various products such as kits and consumables, systems, and software and others. However, the market estimation only comprises manufacturers of molecular diagnostics. The molecular diagnostics market is segmented into five different segments namely products, applications, technologies, end-user, and region. These segments are further segmented into several sub-segments to ease the market estimation and to gain a holistic view of the market. The global market value was estimated using different approaches and validated with one another.

Based on the region, the global molecular diagnostics market is segmented into North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World (RoW). North America is the leading contributor to the global molecular diagnostics market and was responsible for a 46.29% share of the global market values in 2017. However, the Asia-Pacific region is expected to grow at the fastest pace among all other regions with a CAGR of 12.80% during the forecast period 2018-2028.

The key manufacturers who have been contributing significantly to the global molecular diagnostics market include Abbott Laboratories, Agilent Technologies, Inc., Becton, Dickinson and Company, bioMerieux S.A., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Illumina, Inc., QIAGEN N.V., Siemens Healthineers, Inc., and Thermo Fisher Scientific Inc., among others.

Table of Contents

1 Market Overview

  • 1.1 Introduction
  • 1.2 Market Definition
  • 1.3 Historical Perspective
  • 1.4 Significant Technologies
  • 1.5 Classification of Molecular Diagnostics
  • 1.6 Global Footprint
  • 1.7 Future Potential

2 Market Dynamics

  • 2.1 Overview
  • 2.2 Iceberg Analysis - Global Molecular Diagnostics Market
  • 2.3 Impact Analysis
  • 2.4 Market Drivers
    • 2.4.1 A Highly Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
    • 2.4.2 Growth in the Biomarker Identification Market and Advancements in Molecular Techniques
    • 2.4.3 Increase in Awareness and Acceptance of Personalized Medicines on a Global Level
    • 2.4.4 Significant External Funding for Executing Research and Development Exercises
  • 2.5 Market Restraints
    • 2.5.1 Uncertain Reimbursement Scenario
    • 2.5.2 Lack of High-Complexity Testing Centers
    • 2.5.3 Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests
  • 2.6 Market Opportunities
    • 2.6.1 Massive Scope for Adoption of Molecular Diagnostics in Emerging Nations
    • 2.6.2 Increase in the Adoption of Automation & Multiplexing of Technologies
    • 2.6.3 Rise of Next Generation Ultrasensitive Molecular Diagnostics
    • 2.6.4 Novel Revenue Streams

3 Competitive Landscape

  • 3.1 Key Strategies and Developments
    • 3.1.1 Synergistic Activities
    • 3.1.2 Approvals
    • 3.1.3 Product Launches and Enhancements
    • 3.1.4 Acquisitions
    • 3.1.5 Funding and Expansion Activities
  • 3.2 Market Share Analysis
  • 3.3 Growth Share Analysis (Opportunity Mapping)
  • 3.4 Industry Attractiveness
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Threat of New Entrants
    • 3.4.4 Threat of Substitute Products
    • 3.4.5 Intensity of Competitive Rivalry

4 Regulatory Framework

  • 4.1 Legal Requirements and Framework in the U.S.
  • 4.2 Legal Requirements and Framework in Europe
  • 4.3 Legal Requirements and Framework in Asia-Pacific
    • 4.3.1 China
    • 4.3.2 Japan

5 Global Molecular Diagnostics Market (by Product)

  • 5.1 Overview
  • 5.2 Kits and Consumables
  • 5.3 Systems
  • 5.4 Software and Other Products

6 Global Molecular Diagnostics Market (by Application)

  • 6.1 Overview
  • 6.2 Core Molecular Diagnostics
    • 6.2.1 Infectious Diseases
    • 6.2.2 Genetic Testing
    • 6.2.3 Blood Donor Screening
    • 6.2.4 Oncology (Excluding Companion Diagnostics and Liquid Biopsy)
    • 6.2.5 Human Leukocyte Antigen (HLA) Testing
    • 6.2.6 Other Applications
  • 6.3 Non-Invasive Prenatal Testing (NIPT)
  • 6.4 Companion Diagnostics
  • 6.5 Liquid Biopsy

7 Global Molecular Diagnostics Market (by Technology)

  • 7.1 Overview
  • 7.2 Polymerase Chain Reaction (PCR)
  • 7.3 Sequencing
  • 7.4 Microarray
  • 7.5 In-situ Hybridization
  • 7.6 Immunohistochemistry
  • 7.7 Nucleic Acid Amplification
  • 7.8 Isothermal Amplification
  • 7.9 Others

8 Global Molecular Diagnostics Market (by End-User)

  • 8.1 Overview
  • 8.2 Hospitals
  • 8.3 Diagnostic Centers
  • 8.4 Out-Patient Clinics/General Practitioners
  • 8.5 Research Laboratories

9 Global Molecular Diagnostics Market (by Region)

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 The U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 France
    • 9.3.3 Italy
    • 9.3.4 The U.K.
    • 9.3.5 Spain
    • 9.3.6 The Netherlands
    • 9.3.7 Rest-of-Europe
  • 9.4 Asia-Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 Singapore
    • 9.4.6 Rest-of-APAC
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest-of-Latin America
  • 9.6 Rest-of-the-World

10 Company Profiles

  • 10.1 Overview
  • 10.2 Abbott Laboratories
    • 10.2.1 Company Overview
    • 10.2.2 Role of Abbott Laboratories in the Molecular Diagnostics Market
    • 10.2.3 Financials
    • 10.2.4 Key Insights about Financial Health of the Company
    • 10.2.5 SWOT Analysis
  • 10.3 Agilent Technologies, Inc.
    • 10.3.1 Company Overview
    • 10.3.2 Role of Agilent Technologies, Inc. in the Molecular Diagnostics Market
    • 10.3.3 Financials
    • 10.3.4 Key Insights about Financial Health of the Company
    • 10.3.5 SWOT Analysis
  • 10.4 Becton, Dickinson and Company
    • 10.4.1 Company Overview
    • 10.4.2 Role of Becton, Dickinson and Company in the Molecular Diagnostics Market
    • 10.4.3 Financials
    • 10.4.4 Key Insights about Financial Health of the Company
    • 10.4.5 SWOT Analysis
  • 10.5 bioMerieux S.A.
    • 10.5.1 Company Overview
    • 10.5.2 Role of bioMerieux S.A. in the Molecular Diagnostics Market
    • 10.5.3 Financials
    • 10.5.4 Key Insights about Financial Health of the Company
    • 10.5.5 SWOT Analysis
  • 10.6 Bio-Rad Laboratories, Inc.
    • 10.6.1 Company Overview
    • 10.6.2 Role of Bio-Rad Laboratories, Inc. in the Molecular Diagnostics Market
    • 10.6.3 Financials
    • 10.6.4 Key Insights about Financial Health of the Company
    • 10.6.5 SWOT Analysis
  • 10.7 Cynvenio Biosystems, Inc.
    • 10.7.1 Company Overview
    • 10.7.2 Role of Cynvenio Biosystems, Inc. in the Molecular Diagnostics Market
    • 10.7.3 SWOT Analysis
  • 10.8 Danaher Corporation
    • 10.8.1 Company Overview
    • 10.8.2 Role of Danaher Corporation in the Molecular Diagnostics Market
    • 10.8.3 Financials
    • 10.8.4 Key Insights about Financial Health of the Company
    • 10.8.5 SWOT Analysis
  • 10.9 F. Hoffmann-La Roche AG
    • 10.9.1 Company Overview
    • 10.9.2 Role of F. Hoffmann-La Roche AG in the Molecular Diagnostics Market
    • 10.9.3 Financials
    • 10.9.4 Key Insights about Financial Health of the Company
    • 10.9.5 SWOT Analysis
  • 10.10 GUARDANT HEALTH, INC
    • 10.10.1 Company Overview
    • 10.10.2 Role of GUARDANT HEALTH, INC in the Molecular Diagnostics Market
    • 10.10.3 SWOT Analysis
  • 10.11 Illumina, Inc.
    • 10.11.1 Company Overview
    • 10.11.2 Role of Illumina, Inc. in the Molecular Diagnostics Market
    • 10.11.3 Financials
    • 10.11.4 Key Insights about Financial Health of the Company
    • 10.11.5 SWOT Analysis
  • 10.12 Invivoscribe Technologies, Inc.
    • 10.12.1 Company Overview
    • 10.12.2 Role of Invivoscribe Technologies, Inc. in the Molecular Diagnostics Market
    • 10.12.3 SWOT Analysis
  • 10.13 MolecularMD Corporation
    • 10.13.1 Company Overview
    • 10.13.2 Role of MolecularMD Corporation in the Molecular Diagnostics Market
    • 10.13.3 SWOT Analysis
  • 10.14 QIAGEN N.V.
    • 10.14.1 Company Overview
    • 10.14.2 Role of QIAGEN N.V. in the Molecular Diagnostics Market
    • 10.14.3 Financials
    • 10.14.4 Key Insights about Financial Health of the Company
    • 10.14.5 SWOT Analysis
  • 10.15 Siemens Healthineers, Inc.
    • 10.15.1 Company Overview
    • 10.15.2 Role of Siemens Healthineers, Inc. in the Molecular Diagnostics Market
    • 10.15.3 Financials
    • 10.15.4 Key Insights about Financial Health of the Company
    • 10.15.5 SWOT Analysis
  • 10.16 Thermo Fisher Scientific Inc.
    • 10.16.1 Company Overview
    • 10.16.2 Role of Thermo Fisher Scientific Inc. in the Molecular Diagnostics Market
    • 10.16.3 Financials
    • 10.16.4 Key Insights about Financial Health of the Company
    • 10.16.5 SWOT Analysis
  • 10.17 QuantuMDx Group Ltd.
    • 10.17.1 Company Overview
    • 10.17.2 Role of QuantuMDx Group Ltd. In the Molecular Diagnostics Market
  • 10.18 HTG Molecular Diagnostics, Inc.
    • 10.18.1 Company Overview
    • 10.18.2 Role of HTG Molecular Diagnostics, Inc. in the Molecular Diagnostics Market

11 Research Scope and Methodology

  • 11.1 Report Scope
  • 11.2 Global Molecular Diagnostics Market: Research Methodology

List of Tables

  • Table 2.1: Impact Analysis of Market Drivers
  • Table 2.2: Impact Analysis of Market Restraints
  • Table 4.1: Classification rules of IVDs under the IVDR
  • Table 4.2: Registration Criteria for IVD Medical Devices as per the CFDA
  • Table 6.1: Genetic Tests for Certain Applications
  • Table 6.2: Examples of Molecular Diagnostics in Cancer
  • Table 9.1: North America Molecular Diagnostics Market (by Application), 2017-2028
  • Table 9.2: Europe Molecular Diagnostics Market (by Application), 2017-2028
  • Table 9.4: APAC Molecular Diagnostics Market (by Application), 2017-2028
  • Table 9.6: Latin America Molecular Diagnostics Market (by Application), 2017-2028
  • Table 9.7: RoW Molecular Diagnostics Market (by Application), 2017-2028

List of Figures

  • Figure 1: Global Precision Medicine Market, 2016 and 2020
  • Figure 2: Impact of Market Drivers and Market Restraints on the Global Molecular Diagnostics Market
  • Figure 3: Global Molecular Diagnostics Market Snapshot
  • Figure 4: Dominating Segments of the Global Molecular Diagnostics Market, 2017 and 2028
  • Figure 5: Global Molecular Diagnostics Market (by Product), 2017 and 2028
  • Figure 6: Global Molecular Diagnostics Market (by Product), 2017
  • Figure 7: Global Molecular Diagnostics Market (by Product), 2028
  • Figure 8: Global Molecular Diagnostics Market (by Technology), 2017 and 2028
  • Figure 9: Global Molecular Diagnostics Market (by Technology), 2017 and 2028
  • Figure 10: Global Molecular Diagnostics Market (by Technology), 2017 and 2028
  • Figure 1.1: Role of Diagnostics in Healthcare
  • Figure 1.2: Evolution of Molecular Diagnostics
  • Figure 1.3: Classification of Molecular Diagnostics
  • Figure 1.4: Global Molecular Diagnostics (MDx) Market, 2017-2028
  • Figure 2.1: Iceberg Analysis - Global Molecular Diagnostics Market
  • Figure 2.2: Number of Deaths by Top 18 Infectious Diseases, 2015
  • Figure 2.3: Strategies to Integrate Personalized Medicine for Routine Healthcare Procedures
  • Figure 2.4: Benefits of Multiplexing Reactions
  • Figure 3.1: Share of Key Developments and Strategies, January 2016 - December 2018
  • Figure 3 2: Synergistic Activities Share (by Companies), January 2016 - December 2018
  • Figure 3.3: Approvals Share (by Companies), January 2016 - December 2018
  • Figure 3.4: Product Launches and Enhancements Share (by Companies), January 2016 - December 2018
  • Figure 3.5: Acquisitions Share (by Companies), January 2016 - December 2018
  • Figure 3.6: Market Share Analysis for the Global Molecular Diagnostics Market, 2016
  • Figure 3.7: Market Share Analysis for the Global Molecular Diagnostics Market, 2017
  • Figure 3.8: Growth Share Matrix (Opportunity Mapping Matrix) for Global Molecular Diagnostics Market (by companies), 2016
  • Figure 3.9: Growth Share Matrix (Opportunity Mapping Matrix) for Global Molecular Diagnostics Market (by companies), 2017
  • Figure 3.10: Overall Industry Attractiveness, 2018 and 2028
  • Figure 3.11: Overall Impact of Bargaining Power of Suppliers
  • Figure 3.12: Overall Impact of Bargaining Power of Buyers
  • Figure 3.13: Overall Impact of Threat of New Entrants
  • Figure 3.14: Overall Impact of Threat of Substitute Products
  • Figure 3.15: Overall Impact of Intensity of Competitive Rivalry
  • Figure 4.1: Components Considered for Clinical Evidence as per the IVDR
  • Figure 5.1: Global Molecular Diagnostics Market (by Product)
  • Figure 5.2: Global Molecular Diagnostics Market (by Product), 2017 and 2028
  • Figure 5.3: General Workflow of a Molecular Diagnostic Kit
  • Figure 5.4: Global Molecular Diagnostics Market (by Kits and Consumables), 2017-2028
  • Figure 5.5: Global Molecular Diagnostics Market (by Systems), 2017-2028
  • Figure 5.6: Global Molecular Diagnostics Market (by Systems, by Type), 2017-2028
  • Figure 5.7: Aspects of Software Development
  • Figure 5.8: Global Molecular Diagnostics Market (by Software and Other Products), 2017-2028
  • Figure 6.1: Global Molecular Diagnostics Market (by Application)
  • Figure 6.2: Global Molecular Diagnostics Market (by Application), 2017
  • Figure 6.3: Global Molecular Diagnostics Market (by Application), 2028
  • Figure 6.4: Global Molecular Diagnostics Market (by Core MDx Applications), 2017 and 2028
  • Figure 6.5: Nucleic Acid Testing Techniques for Infectious Diseases
  • Figure 6.6: Global Molecular Diagnostics Market (by Infectious Diseases), 2017-2028
  • Figure 6.7: Global Molecular Diagnostics Market (by Infectious Diseases), 2017 and 2028
  • Figure 6.8: Global Molecular Diagnostics Market (by Infectious Diseases, by Technology), 2017 and 2028
  • Figure 6.9: Global Molecular Diagnostics Market (by Genetic Testing), 2017-2028
  • Figure 6.10: Global Molecular Diagnostics Market (by Genetic Testing, by Technology), 2017 and 2028
  • Figure 6.11: Global Molecular Diagnostics Market (by Blood Donor Screening), 2017-2028
  • Figure 6.12: Clinical Uses of Molecular Diagnostics in Cancer
  • Figure 6.13: Global Molecular Diagnostics Market (by Cancer), 2017-2028
  • Figure 6.14: Global Molecular Diagnostics Market (by Oncology), 2017 and 2028
  • Figure 6.15: Global Molecular Diagnostics Market (by Oncology, by Technology), 2017 and 2028
  • Figure 6.16: Global Molecular Diagnostics Market (by HLA Testing), 2017-2028
  • Figure 6.17: Global Molecular Diagnostics Market (by Other Applications), 2017-2028
  • Figure 6.18: Global Molecular Diagnostics Market (by Companion Diagnostics), 2017 and 2028
  • Figure 6.19: Global Molecular Diagnostics Market (by NIPT, by Technology), 2017 and 2028
  • Figure 6.20: Global Molecular Diagnostics Market (by Companion Diagnostics), 2017 and 2028
  • Figure 6.21: Global Molecular Diagnostics Market (by Companion Diagnostics, by Technology), 2017 and 2028
  • Figure 6.22: Global Molecular Diagnostics Market (by Liquid Biopsy), 2017 and 2028
  • Figure 6.23: Global Molecular Diagnostics Market (by Liquid Biopsy, by Technology), 2017 and 2028
  • Figure 7.1: Global Molecular Diagnostics Market (by Technology)
  • Figure 7.2: Global Molecular Diagnostics Market (by Technology), 2017
  • Figure 7.3: Global Molecular Diagnostics Market (by PCR), 2017-2028
  • Figure 7.4: Evolution of Sequencing for Molecular Diagnostics
  • Figure 7.5: Global Molecular Diagnostics Market (by Sequencing), 2017-2028
  • Figure 7.6: Global Molecular Diagnostics Market (by Microarray), 2017-2028
  • Figure 7.7: Global Molecular Diagnostics Market (by ISH), 2017-2028
  • Figure 7.8: Global Molecular Diagnostics Market (by IHC), 2017-2028
  • Figure 7.9: Global Molecular Diagnostics Market (by NAA), 2017-2028
  • Figure 7.10: Global Molecular Diagnostics Market (by Isothermal Amplification), 2017-2028
  • Figure 7.11: Global Molecular Diagnostics Market (by Other Technologies), 2017-2028
  • Figure 8.1: Global Molecular Diagnostics Market (by End-User)
  • Figure 8.2: Global Molecular Diagnostics Market (by End-User), 2017 and 2028
  • Figure 8.3: Global Molecular Diagnostics Market (by Hospitals), 2017-2028
  • Figure 8.4: Global Molecular Diagnostics Market (by Diagnostic Centers), 2017-2028
  • Figure 8.5: Global Molecular Diagnostics Market (by Out-Patient Clinics/GPs), 2017-2028
  • Figure 8.6: Global Molecular Diagnostics Market (by Research Laboratories), 2017-2028
  • Figure 9.1: Global Molecular Diagnostics Market (by Region), 2017 and 2028
  • Figure 9.2: Global Molecular Diagnostics Market (by Region), 2017-2028
  • Figure 9.3: Global Molecular Diagnostics Market Share (by Region), 2017
  • Figure 9.4: Global Molecular Diagnostics Market Share (by Region), 2028
  • Figure 9.5: North America Molecular Diagnostics Market, 2017-2028
  • Figure 9.6: North America: Market Dynamics
  • Figure 9.7: North America Molecular Diagnostics Market (by Country), 2017-2028
  • Figure 9.8: The U.S. Molecular Diagnostics Market, 2017-2028
  • Figure 9.9: Canada Molecular Diagnostics Market, 2017-2028
  • Figure 9.10: Overview of Reimbursement Policies in Europe (Focus on Companion Diagnostics as well)
  • Figure 9.11: Europe Molecular Diagnostics Market, 2017-2028
  • Figure 9.12: Europe: Market Dynamics
  • Figure 9.13: Europe Molecular Diagnostics Market (by Country), 2017-2028
  • Figure 9.14: Germany Molecular Diagnostics Market, 2017-2028
  • Figure 9.15: France Molecular Diagnostics Market, 2017-2028
  • Figure 9.16: Italy Molecular Diagnostics Market, 2017-2028
  • Figure 9.17: The U.K. Molecular Diagnostics Market, 2017-2028
  • Figure 9 18: Spain Molecular Diagnostics Market, 2017-2028
  • Figure 9.19: The Netherlands Molecular Diagnostics Market, 2017-2028
  • Figure 9.20: Rest-of-Europe Molecular Diagnostics Market, 2017-2028
  • Figure 9.21: Asia-Pacific Molecular Diagnostics Market, 2017-2028
  • Figure 9.22: APAC: Market Dynamics
  • Figure 9.23: APAC Molecular Diagnostics Market (by Country), 2017-2028
  • Figure 9.24: Japan Molecular Diagnostics Market, 2017-2028
  • Figure 9.25: China Molecular Diagnostics Market, 2017-2028
  • Figure 9.26: India Molecular Diagnostics Market, 2017-2028
  • Figure 9.27: Australia Molecular Diagnostics Market, 2017-2028
  • Figure 9.28: Singapore Molecular Diagnostics Market, 2017-2028
  • Figure 9.29: RoAPAC Molecular Diagnostics Market, 2017-2028
  • Figure 9.30: Latin America Molecular Diagnostics Market, 2017-2028
  • Figure 9.31: Latin America: Market Dynamics
  • Figure 9.32: Latin America Molecular Diagnostics Market (by Country), 2017-2028
  • Figure 9.33: Brazil Molecular Diagnostics Market, 2017-2028
  • Figure 9.34: Mexico Molecular Diagnostics Market, 2017-2028
  • Figure 9.35: Rest-of-Latin America Molecular Diagnostics Market, 2017-2028
  • Figure 9.36: RoW Molecular Diagnostics Market, 2017-2028
  • Figure 10.1: Total Number of Companies Profiled
  • Figure 10.2: Abbott Laboratories: Overall Product Portfolio
  • Figure 10.3: Abbott Laboratories: Overall Financials, 2015-2017
  • Figure 10.4: Abbott Laboratories: Revenue (by Segment), 2015-2017
  • Figure 10.5: Abbott Laboratories: Revenue Split for Diagnostics, 2015-2017
  • Figure 10.6: Abbott Laboratories: Revenue (by Region), 2015-2017
  • Figure 10.7: Abbott Laboratories: R&D Expenditure, 2015-2017
  • Figure 10.8: Abbott Laboratories: Revenue Forecast, 2015-2020
  • Figure 10.9: Abbott Laboratories: SWOT Analysis
  • Figure 10.10: Agilent Technologies, Inc.: Overall Product Portfolio
  • Figure 10.11: Agilent Technologies, Inc.: Overall Financials, 2015-2017
  • Figure 10.12: Agilent Technologies, Inc.: Revenue (by Segment), 2015-2017
  • Figure 10.13: Agilent Technologies, Inc.: Revenue (by Region), 2015-2017
  • Figure 10.14: Agilent Technologies, Inc.: R&D Expenditure, 2015-2017
  • Figure 10.15: Agilent Technologies, Inc.: Revenue Forecast, 2015-2020
  • Figure 10.16: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 10.17: Becton, Dickinson and Company: Overall Product Portfolio
  • Figure 10.18: Becton, Dickinson and Company: Overall Financials, 2015-2017
  • Figure 10.19: Becton, Dickinson and Company: Revenue (by Segment), 2015-2017
  • Figure 10.20: Becton, Dickinson and Company: Revenue Split for BD Life Sciences, 2015-2017
  • Figure 10.21: Becton, Dickinson and Company: Revenue (by Region), 2015-2017
  • Figure 10.22: Becton, Dickinson and Company: R&D Expenditure, 2015-2017
  • Figure 10.23: Becton, Dickinson and Company: Revenue Forecast, 2015-2020
  • Figure 10.24: Becton, Dickinson and Company: SWOT Analysis
  • Figure 10.25: bioMerieux S.A.: Overall Product Portfolio
  • Figure 10.26: bioMerieux S.A.: Overall Financials, 2015-2017
  • Figure 10.27: bioMerieux S.A.: Revenue (by Segment), 2015-2017
  • Figure 10.28: bioMerieux S.A.: Revenue (by Region), 2015-2017
  • Figure 10.29: bioMerieux S.A.: R&D Expenditure, 2015-2017
  • Figure 10.30: bioMerieux S.A.: Revenue Forecast, 2015-2020
  • Figure 10.31: bioMerieux S.A.: SWOT Analysis
  • Figure 10.32: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
  • Figure 10.33: Bio-Rad Laboratories, Inc.: Overall Financials, 2015-2017
  • Figure 10.34: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2015-2017
  • Figure 10.35: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2015-2017
  • Figure 10.36: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2015-2017
  • Figure 10.37: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 10.38: Cynvenio Biosystems, Inc.: Overall Product Portfolio
  • Figure 10.39: Cynvenio Biosystems, Inc.: SWOT Analysis
  • Figure 10.40: Danaher Corporation: Overall Product Portfolio
  • Figure 10.41: Danaher Corporation: Overall Financials, 2015-2017
  • Figure 10.42: Danaher Corporation: Revenue (by Segment), 2015-2017
  • Figure 10.43: Danaher Corporation: Revenue Split for Diagnostics, 2015-2017
  • Figure 10.44: Danaher Corporation: Revenue (by Region), 2015-2017
  • Figure 10.45: Danaher Corporation: R&D Expenditure, 2015-2017
  • Figure 10.46: Danaher Corporation: Revenue Forecast, 2015-2020
  • Figure 10.47: Danaher Corporation: SWOT Analysis
  • Figure 10.48: F. Hoffmann-La Roche AG: Overall Product Portfolio
  • Figure 10.49: F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
  • Figure 10.50: F. Hoffmann-La Roche AG: Revenue (by Segment), 2015-2017
  • Figure 10.51: F. Hoffmann-La Roche AG: Revenue Split for Diagnostics, 2015-2017
  • Figure 10.52: F. Hoffmann-La Roche AG: Revenue (by Region), 2015-2017
  • Figure 10.53: F. Hoffmann-La Roche AG: R&D Expenditure, 2015-2017
  • Figure 10.54: F. Hoffmann-La Roche AG: Revenue Forecast, 2015-2020
  • Figure 10.55: F. Hoffmann-La Roche AG: SWOT Analysis
  • Figure 10.56: GUARDANT HEALTH, INC: Overall Product Portfolio
  • Figure 10.57: GUARDANT HEALTH, INC: SWOT Analysis
  • Figure 10.58: Illumina, Inc.: Overall Product Portfolio
  • Figure 10.59: Illumina, Inc.: Overall Financials, 2015-2017
  • Figure 10.60: Illumina, Inc.: Revenue (by Segment), 2015-2017
  • Figure 10.61: Illumina, Inc.: Revenue (by Region), 2015-2017
  • Figure 10.62: Illumina, Inc.: R&D Expenditure, 2015-2017
  • Figure 10.63: Illumina, Inc.: Revenue Forecast, 2015-2020
  • Figure 10.64: Illumina, Inc.: SWOT Analysis
  • Figure 10.65: Invivoscribe Technologies, Inc.: Overall Product Portfolio
  • Figure 10.66: Invivoscribe Technologies, Inc.: SWOT Analysis
  • Figure 10.67: MolecularMD Corporation: Overall Product Portfolio
  • Figure 10.68: MolecularMD Corporation: SWOT Analysis
  • Figure 10.69: QIAGEN N.V.: Overall Product Portfolio
  • Figure 10.70: QIAGEN N.V.: Overall Financials, 2015-2017
  • Figure 10.71: QIAGEN N.V.: Revenue (by Segment), 2015-2017
  • Figure 10.72: QIAGEN N.V.: Revenue (by Region), 2015-2017
  • Figure 10.73: QIAGEN N.V.: R&D Expenditure, 2015-2017
  • Figure 10.74: QIAGEN N.V.: Revenue Forecast, 2015-2020
  • Figure 10.75: QIAGEN N.V.: SWOT Analysis
  • Figure 10.76: Siemens Healthineers, Inc.: Overall Product Portfolio
  • Figure 10.77: Siemens Healthineers, Inc.: Overall Financials, 2016-2018
  • Figure 10.78: Siemens Healthineers, Inc.: Revenue (by Segment), 2016-2018
  • Figure 10.79: Siemens Healthineers, Inc.: Revenue (by Region), 2016-2018
  • Figure 10.80: Siemens Healthineers, Inc.: R&D Expenditure, 2016-2018
  • Figure 10.81: Siemens Healthineers, Inc.: Revenue Forecast, 2015-2020
  • Figure 10.82: Siemens Healthineers, Inc.: SWOT Analysis
  • Figure 10.83: Thermo Fisher Scientific Inc.: Overall Product Portfolio
  • Figure 10.84: Thermo Fisher Scientific Inc.: Overall Financials, 2015-2017
  • Figure 10.85: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2015-2017
  • Figure 10.86: Thermo Fisher Scientific Inc.: Revenue (by Region), 2015-2017
  • Figure 10.87: Thermo Fisher Scientific Inc.: R&D Expenditure, 2015-2017
  • Figure 10.88: Thermo Fisher Scientific Inc.: Revenue Forecast, 2015-2020
  • Figure 10.89: Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 10.90: QuantuMDx Group Ltd.: Overall Product Portfolio (Available from FY2019)
  • Figure 10.91: HTG Molecular Diagnostics, Inc.: Overall Product Portfolio
  • Figure 11.1: Global Molecular Diagnostics Market Segmentation
  • Figure 11.2: Global Molecular Diagnostics Market Research Methodology
  • Figure 11.3: Primary Research
  • Figure 11.4: Secondary Research
  • Figure 11.5: Data Triangulation
  • Figure 11.6: Bottom-up Approach (Segment-wise Analysis)
  • Figure 11.7: Top-down Approach (Segment-wise Analysis)
  • Figure 11.8: Assumptions and Limitations
  • Figure 11.9: Considered Factors for Data Prediction and Modeling
Back to Top